Welcome to LookChem.com Sign In|Join Free

CAS

  • or

38821-49-7

Post Buying Request

38821-49-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

38821-49-7 Usage

Description

Carbidopa, also known as (S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid, is a white crystalline powder that is slightly soluble in water with a pKa of 7.8. It is a peripheral decarboxylase inhibitor and a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa is metabolized into two main metabolites, which are primarily eliminated in the urine, either unchanged or as glucuronide conjugates. It is used in the management of Parkinson's disease and has no antiparkinson activity by itself but helps reduce the peripheral adverse effects of levodopa. Carbidopa is a member of hydrazines, a hydrate, a monocarboxylic acid, and a member of catechols.

Uses

Used in Parkinson's Disease Research:
Carbidopa is used as a dopa decarboxylase inhibitor for the research of Parkinson's disease. It prevents the conversion of levodopa to dopamine, thus reducing the peripheral adverse effects of levodopa and enhancing its effectiveness in treating Parkinson's disease.
Used in Pancreatic Cancer Research:
Carbidopa is used as an inhibitor of pancreatic cancer cell and tumor growth, providing a potential therapeutic approach for pancreatic cancer treatment.
Used as a Pharmaceutical Reference Standard:
Carbidopa may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by chromatography techniques, ensuring the quality and consistency of the drug in various applications.
Used in Drug Formulations:
Carbidopa is combined with levodopa for the treatment of Parkinson's disease and Parkinson's syndrome, providing a more effective and safer treatment option by reducing the peripheral conversion of levodopa to dopamine and minimizing side effects.

Check Digit Verification of cas no

The CAS Registry Mumber 38821-49-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,8,2 and 1 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 38821-49:
(7*3)+(6*8)+(5*8)+(4*2)+(3*1)+(2*4)+(1*9)=137
137 % 10 = 7
So 38821-49-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2

38821-49-7 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (C2450)  Carbidopa Monohydrate  >98.0%(HPLC)(T)

  • 38821-49-7

  • 100mg

  • 440.00CNY

  • Detail
  • TCI America

  • (C2450)  Carbidopa Monohydrate  >98.0%(HPLC)(T)

  • 38821-49-7

  • 1g

  • 1,980.00CNY

  • Detail
  • Sigma-Aldrich

  • (C0460000)  Carbidopa  European Pharmacopoeia (EP) Reference Standard

  • 38821-49-7

  • C0460000

  • 1,880.19CNY

  • Detail
  • Sigma-Aldrich

  • (Y0001713)  Carbidopa for system suitability  European Pharmacopoeia (EP) Reference Standard

  • 38821-49-7

  • Y0001713

  • 1,880.19CNY

  • Detail
  • USP

  • (1095506)  Carbidopa  United States Pharmacopeia (USP) Reference Standard

  • 38821-49-7

  • 1095506-400MG

  • 4,662.45CNY

  • Detail

38821-49-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name carbidopa

1.2 Other means of identification

Product number -
Other names Carbidopa

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:38821-49-7 SDS

38821-49-7Downstream Products

38821-49-7Relevant articles and documents

Asymmetric Synthesis of L-carbidopa based on a highly enantioselective α-amination

Pericas, Lex,Shafir, Alexandr,Vallribera, Adelina

supporting information, p. 1448 - 1451 (2013/06/27)

A stereoselective synthesis of l-carbidopa in seven steps and 50% overall yield from commercial compounds is described. The key step involves a highly enantioselective α-amination reaction of an acyclic β-ketoester with di-tert-butyl azodicarboxylate indu

Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core

-

, (2008/06/13)

A tablet which comprises: an inner core formulated for controlled release comprising a mixture of (a) a granulated admixture of a decarboxylase inhibitor and a surfactant, and (b) levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 38821-49-7